Early identification of CHB-LTBI co-infection could guide clinicians to modify management of both CHB and LTBI to reduce the risk of drug-induced liver injury. Chronic hepatitis B (CHB) and latent tuberculosis (LTBI) remain major infectious diseases that contribute to significant morbidity and mortality worldwide. While both CHB and LTBI manifest with different clinical phenotypes, with one being primarily a liver